We Are Innovators

WE ARE REFLEXION

ABOUT

AN ENTIRELY NEW CLASS OF THERAPEUTICS:  SYNTHETIC D-PROTEINS

Reflexion Pharmaceuticals has developed a novel platform utilizing the tools of synthetic biology to discover, develop and deliver an exciting new class of drug products:  completely synthetic proteins composed entirely of D-amino acids.  These synthetic D-proteins exhibit the benefits of antibodies while overcoming many of their limitations including reduced size, no immunogenicity, and improved stability.  Our platform technology allows us to pursue virtually any disease target and shows enormous potential.

 
 

TECH

ENGINEERING  MIRROR-IMAGE  MEDICINE

We use a technique called mirror-image phage display to engineer synthetic D-protein therapies against a broad range of disease targets.  After we identify our target protein in its naturally occurring L-form, we chemically synthesize its mirror-image enantiomer using D-amino acids.  We then use several rounds of phage display to evolve high-affinity binding variants against this mirror-image of the disease target.  Finally, we chemically synthesize these binders as D-proteins that act as highly potent antagonists to the disease targets in vivo.

ADVANTAGES

Circle.png
Magnifying.png

SMALL SIZE

Our synthetic D-proteins are 20X smaller than antibodies yet have equivalent potencies, allowing higher molar concentrations to be used

Scissors.png
Circle.png

NON-IMMUNOGENIC

Synthetic D-proteins are resistant to degradation by proteases, extending their residence time and preventing the activation of anti-drug immune responses

Fire.png
Circle.png

THERMAL STABILITY

Our D-proteins are engineered for high thermal and chemical stability, eliminating the need for a cold chain

D Proteins.jpg
 

OUR  THERAPEUTIC  PIPELINE

ASSETS

ANTI-
PD-1

PD-1 inhibitors are the most exciting class of therapeutics to be discovered in the last decade.  These molecules release the "brakes" on our immune systems, stimulating a full-on assault against cancerous cells 

IMMUNO-ONCOLOGY

ANTI-

PD-1

ANTI-
VEGF

VEGF is a primary target for treatment of wet macular degeneration, and has recently demonstrated tremendous success in the clinic in combination with PD-1 inhibitors for treating a number of different cancers 

MACULAR DEGENERATION, ONCOLOGY

ANTI-

VEGF

 

TEAM

WHO  WE  ARE

Dana.jpg

DANA AULT-RICHE, PHD

Dave.jpeg

DAVID CHERNOFF, MD

Greg.jpg

GREG WENT, PHD

Marcy.jpeg

KYLE LANDGRAF, PHD

MARCY BETH NANUS

Natalie.jpeg

NATALIE MCLURE, PHD

Paul.jpg

PAUL STEPHEN MARINEC, PHD

Rich.png

RICHARD VAN DEN BROEK

Rowan.jpeg

ROWAN CHAPMAN, PHD

Dev.jpg
Ved.jpeg

SACHDEV SIDHU, PHD

STEPHEN KENT, PHD

VED SRIVASTAVA, PHD

Kyle.jpg
Steve.jpg
 

GET IN TOUCH

We'll be in touch shortly!